Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 465-481

  Kontoghiorghe, Christina N ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Deferasirox; Deferiprone; Deferoxamine; Efficacy; Iron absorption; Iron overload; Safety; Thalassemia intermedia

Indexed keywords

8 QUINOLINOL; ASCORBIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; HEMOGLOBIN; IRON; MALTOL; PLACEBO; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; ARTHRALGIA; BONE MARROW DEPRESSION; CLINICAL PROTOCOL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; EAR DISEASE; ELIMINATION HALF-LIFE; ERYTHROCYTE TRANSFUSION; EYE DISEASE; HEART DISEASE; HUMAN; INDIVIDUALIZATION; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LIVER DISEASE; MORBIDITY; MORTALITY; MUCORMYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SPLENECTOMY; STOMACH DISEASE; SURVIVAL RATE; THALASSEMIA INTERMEDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; YERSINIOSIS; ZINC DEFICIENCY; CHELATION THERAPY; COMPLICATION; PROCEDURES; SYNDROME; THALASSEMIA;

BENZOATES; CHELATION THERAPY; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; SYNDROME; THALASSEMIA; TRIAZOLES;

EID: 84957568809     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S79458     Document Type: Review

References (119)

1. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705–5724.
2. Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112(2):219–230.
3. [No authors listed]. Community control of hereditary anaemias: memorandum from a WHO meeting. Bull World Health Organ. 1983;61(1):63–80.
4. Weatherall DJ, Glegg JB. The Thalassaemia Syndromes. 3rd ed. Oxford: Blackwell Scientific Publications; 1981.
5. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):339–408.
6. Barton JC, Edwards CQ. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge: Cambridge University Press; 2000.
7. Halliwell B, Gutteridge JM. Free radicals and antioxidant protection: mechanisms and significance in toxicology and disease. Hum Toxicol. 1988;7(1):7–13.
8. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed). 2009;1:161–178.
9. Singer ST. Variable clinical phenotypes of α-thalassemia syndromes. ScientificWorldJournal. 2008;9:615–625.
10. Galanello R, Cao A. Relationship between genotype and phenotype: thalassemia intermedia. Ann NY Acad Sci. 1998;850:325–333.
11. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291–304.
12. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassaemia intermedia. Lancet. 1979;2(8147):819–821.
13. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124–1129.
14. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663–2681.
15. Kontoghiorghes GJ, Spyrou A, Kolnagou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption. Hemoglobin. 2010;34(3):251–264.
16. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92(5):658–665.
17. Sonakul D, Pacharee P, Wasi P, Fucharoen S. Cardiac pathology in 47 patients with β-thalassaemia/haemoglobin E. Southeast Asian J Trop Med Public Health. 1984;15(4):554–563.
18. Aessopos A, Farmakis D, Trompoukis C, et al. Cardiac involvement in sickle β-thalassemia. Ann Hematol. 2009;88(6):557–564.
19. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411–3416.
20. Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian registry. Br J Haematol. 2014;167(1):121–126.
21. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin. 2010;34(3):221–226.
22. Taher AT, Porter JB, Viprakasit V, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol. 2014;92(6):521–526.
23. Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332–338.
24. Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. Transition of thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol. 2014;4(4):197–218.
25. Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: orphan and rare diseases, orphan drugs and orphan patients. World J Methodol. 2014;4(3):163–188.
26. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Curr Med Chem. 2005;12(23):2695–2709.
27. Fucharoen S, Ketvichit P, Pootrakul P, Siritanaratkul N, Piankijagum A, Wasi P. Clinical manifestation of β-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2000;22(6):552–557.
28. Vichinsky E. Hemoglobin E syndromes. Hematology Am Soc Hematol Educ Program. 2007:79–83.
29. Pantopoulos K. Function of the hemochromatosis protein HFE: lessons from animal models. World J Gastroenterol. 2008;14(45):6893–6901.
30. Byrnes V, Barrett S, Ryan E, et al. Increased duodenal DMT-1 expression and unchanged HFE mRNA levels in HFE-associated hereditary hemochromatosis and iron deficiency. Blood Cells Mol Dis. 2002;29(3):251–260.
31. Mavrogeni S, Gotsis E, Ladis V, et al. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and β-thalassemia major. Int J Cardiovasc Imaging. 2008;24(8):849–854.
32. Au WY, Lam WW, Chu WW, et al. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann Hematol. 2009;88(10):947–950.
33. Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittelforschung. 1990;40(12):1332–1335.
34. Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in β-thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1–2):10–15.
35. Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131(3):378–388.
36. Patrinos GP, Grosvelt FG. Pharmacogenomics and therapeutics of haemoglobinopathies. Hemoglobin. 2008;32(1–2):229–236.
37. Olivieri NF, Freedman MH, Perrine SP, et al. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood. 1992;80(12):3258–3260.
38. Adekile AD, Azab AF, Al-Sharida SI, et al. Clinical and molecular characteristics of non-transfusion-dependent thalassemia in Kuwait. Hemoglobin. 2015;39(5):320–326.
39. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003;26(8):553–584.
40. Kontoghiorghes GJ. Structure/red blood cell permeability activity of iron(III) chelator complexes. Inorganica Chim Acta. 1988;151(2):101–106.
41. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met. 1990;3(3–4):183–187.
42. Forsbeck K, Nilsson K, Kontoghiorghes GJ. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes. Eur J Haematol. 1987;39(4):318–325.
43. Yamamoto RS, Williams GM, Frangel HH, Weisburger JH. 8-Hydroxyquinoline:chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide. Toxicol Appl Pharmacol. 1971;19(4):687–698.
44. Kontoghiorghes GJ. The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia [doctoral thesis]. Colchester, UK: University of Essex; 1982.
45. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998;12(9):845–848.
46. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579–588.
47. Kontoghiorghes GJ. Do we need more iron-chelating drugs? Lancet. 2003;362(9382):495–496.
48. Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6):608–615.
49. Dresow B, Fischer R, Nielsen P, Gabbe EE, Piga A. Effect of oral iron chelator L1 on iron absorption in man. Ann N Y Acad Sci. 1998;850:466–468.
50. Berkovitch M, Livne A, Lushkov G, et al. The efficacy of oral deferiprone in acute iron poisoning. Am J Emerg Med. 2000;18(1):36–40.
51. Djaldetti M, Fishman P, Notti I, Bessler H. The effect of tetracycline administration on iron absorption in mice. Biomedicine. 1981;35(5):150–152.
52. Konstantinou E, Pashalidis I, Kolnagou A, Kontoghiorghes GJ. Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies. Hemoglobin. 2011;35(3):237–246.
53. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30.
54. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2052.
55. Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777–1778.
56. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin. 2008;32(1–2):1–15.
57. Cohen AR. Iron chelation therapy: you gotta have heart. Blood. 2010;115(12):2333–2334.
58. Dézsi L, Vécsei L. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson’s drugs. Expert Opin Drug Metab Toxicol. 2014;10(3):409–424.
59. Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung. 1995;45(1):65–69.
60. Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol. 2007;86(3):212–215.
61. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in β-thalassemia. MAGMA. 1998;6(1):7–12.
62. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179.
63. Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin. 2009;33(5):312–322.
64. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054:373–378.
65. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5):430–438.
66. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.
67. Kolnagou A, Kontoghiorghes GJ. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy. Hemoglobin. 2010;34(3):204–209.
68. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin. 2011;35(3):186–198.
69. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
70. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537–543.
71. Vlachaki E, Agapidou A, Spanos G, et al. Five years of deferasirox therapy for cardiac iron in β-thalassemia major. Hemoglobin. 2015;39(5):299–304.
72. Meerpohl JJ, Antes G, Rücker G, et al. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2012;2:CD007476.
73. Wasi P, Pootrakul P, Fucharoen S, Winichagoon P, Wilairat P, Promboon A. Thalassemia in southeast Asia: determination of different degrees of severity of anemia in thalassemia. Ann N Y Acad Sci. 1985;445:119–126.
74. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2):201–206.
75. US Food and Drug Administration. Clinical review: Exjade (deferasirox, ICL-670). 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4177B1_02_b.pdf. Accessed December 1, 2015.
76. Exjade (deferasirox) tablets for oral suspension [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf. Accessed December 1, 2015.
77. Kontoghiorghes GJ. A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf. 2013;12(5):605–609.
78. Kontoghiorghes GJ. Turning a blind eye to deferasirox’s toxicity? Lancet. 2013;381(9873):1183–1184.
79. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18(6):660–667.
80. Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol. 1985;20(4):153–156.
81. Cases A, Kelly J, Sabater F, et al. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron. 1990;56(1):19–23.
82. Boddaert N, Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408.
83. Rajapurkar MM, Hegde U, Bhattacharya A, Alam MG, Shah SV. Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease. Toxicol Mech Methods. 2013;23(1):5–10.
84. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583–1587.
85. Pootrakul P, Vongsmasa V, Laongpanich P, Wasi P. Serum ferritin levels in thalassemias and the effect of splenectomy. Acta Haematol. 1981;66(4):244–250.
86. Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia. Eur J Pediatr. 1981;137(3):267–271.
87. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123(5):952–953.
88. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305–310.
89. Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol. 2006;133(2):198–205.
90. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79(10):2741–2748.
91. Calvaruso G, Vitrano A, Di Maggio R, et al. Deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial. Am J Hematol. 2015;90(7):634–638.
92. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007;109(1):362–364.
93. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977.
94. ®) in modulation of iron overload in patients with β-thalassemia intermedia. Hemoglobin. 2015;39(5):327–329.
95. Al-Khabori M, Bhandari S, Al-Huneini M, Al-Farsi K, Panjwani V, Daar S. Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia. Oman Med J. 2013;28(2):121–124.
96. Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with β-thalassaemia. Br J Haematol. 2014;167(3):434–436.
97. Chuang GT, Tsai IJ, Tsau YK, Lu MY. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Nephrology (Carlton). 2015;20(12):931–935.
98. Naderi M, Sadeghi-Bojd S, Valeshabad AK, et al. A prospective study of tubular dysfunction in pediatric patients with β-thalassemia major receiving deferasirox. Pediatr Hematol Oncol. 2013;30(8):748–754.
99. Teawtrakul N, Chansung K, Sirijerachai C, Wanitpongpun C, Thepsuthammarat K. The impact and disease burden of thalassemia in Thailand: a population-based study in 2010. J Med Assoc Thai. 2012;95 Suppl 7:S211–S216.
100. ®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88(4):251–260.
101. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions: comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30(2):329–947.
102. Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62(9):1592–1596.
103. Cassinerio E, Orofino N, Roghi A, et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014;53(3):164–167.
104. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95(5):411–420.
105. Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ. The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients. Toxicol Mech Methods. 2013;23(1):34–41.
106. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther. 1990;48(3):255–261.
107. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38(5):808–816.
108. Cao H. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology. 2004;9(3):223–233.
109. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014;35(3):155–161.
110. Arezes J, Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol. 2015;37 Suppl 1:92–98.
111. Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. Selection of a new generation of orally active α-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am J Hematol. 1993;42(4):340–349.
112. Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals. Expert Opin Investig Drugs. 2013;22(5):591–618.
113. Vreugdenhil G, Swaak AJ, de Jeu-Jaspers C, van Eijk HG. Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis. 1990;49(11):956–957.
114. Evans RW, Sharma M, Ogwang W, Patel KJ, Bartlett AN, Kontoghiorghes GJ. The effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today. 1992;28 Suppl A:9–23.
115. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996;51(3):243–244.
116. Chang YH, Shaw CF, Wu KH, Hsieh KH, Su YN, Lu PJ. Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. Hemoglobin. 2009;33(5):346–351.
117. Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, van Eijk HG. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet. 1989;2(8676):1398–1399.
118. Mostert LJ, Van Dorst JA, Koster JF, Van Eijk HG, Kontoghiorghes GJ. Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte. Free Radic Res Commun. 1987;3(6):379–388.
119. Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages. Am J Hematol. 1990;34(1):21–25.